Literature DB >> 16386250

Dominant-negative effect of mutant valosin-containing protein in aggresome formation.

Makiko-Iijima Kitami1, Toshiaki Kitami, Masami Nagahama, Mitsuo Tagaya, Seiji Hori, Akira Kakizuka, Yoshikuni Mizuno, Nobutaka Hattori.   

Abstract

Lewy bodies (LBs) are the pathologic hallmark of Parkinson's disease. Recent studies revealed that LBs exhibit several morphologic and molecular similarities to aggresomes. Aggresomes are perinuclear aggregates representing intracellular deposits of misfolded proteins. Recently, valosin-containing protein (VCP) was one of the components of LBs, suggesting its involvement in LB formation. Here, we showed the localization of VCP in aggresomes induced by a proteasome inhibitor in cultured cells. Cells overexpressing mutant VCP (K524M: D2) showed reduced aggresome formation relative to those overexpressing wild-type and mutant (K251M: D1) VCPs. Our findings suggest that the D2 domain is involved in aggresome formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386250     DOI: 10.1016/j.febslet.2005.12.044

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Recruitment of the oncoprotein v-ErbA to aggresomes.

Authors:  Cornelius Bondzi; Abigail M Brunner; Michelle R Munyikwa; Crystal D Connor; Alicia N Simmons; Stephanie L Stephens; Patricia A Belt; Vincent R Roggero; Manohara S Mavinakere; Shantá D Hinton; Lizabeth A Allison
Journal:  Mol Cell Endocrinol       Date:  2010-11-12       Impact factor: 4.102

2.  Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

Authors:  Paola Magnaghi; Roberto D'Alessio; Barbara Valsasina; Nilla Avanzi; Simona Rizzi; Daniela Asa; Fabio Gasparri; Liviana Cozzi; Ulisse Cucchi; Christian Orrenius; Paolo Polucci; Dario Ballinari; Claudia Perrera; Antonella Leone; Giovanni Cervi; Elena Casale; Yang Xiao; Chihunt Wong; Daniel J Anderson; Arturo Galvani; Daniele Donati; Tom O'Brien; Peter K Jackson; Antonella Isacchi
Journal:  Nat Chem Biol       Date:  2013-07-28       Impact factor: 15.040

3.  Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection.

Authors:  Minetaro Arita; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis.

Authors:  Ian Tran; Changhoon Ji; Inzer Ni; Taehong Min; Danni Tang; Neeraj Vij
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

Review 5.  Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.

Authors:  Conrad C Weihl; Alan Pestronk; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-04-19       Impact factor: 4.296

6.  Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease.

Authors:  Jeong-Sun Ju; Sara E Miller; Phyllis I Hanson; Conrad C Weihl
Journal:  J Biol Chem       Date:  2008-08-20       Impact factor: 5.157

7.  The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation.

Authors:  Changcheng Song; Zhen Xiao; Kunio Nagashima; Chou-Chi H Li; Stephen J Lockett; Ren-Ming Dai; Edward H Cho; Thomas P Conrads; Timothy D Veenstra; Nancy H Colburn; Qing Wang; Ji Ming Wang
Journal:  Toxicol Appl Pharmacol       Date:  2008-01-08       Impact factor: 4.219

8.  Aggrephagy: selective disposal of protein aggregates by macroautophagy.

Authors:  Trond Lamark; Terje Johansen
Journal:  Int J Cell Biol       Date:  2012-03-22

9.  AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential.

Authors:  Neeraj Vij
Journal:  J Cell Mol Med       Date:  2008-08-09       Impact factor: 5.310

Review 10.  Granulostasis: Protein Quality Control of RNP Granules.

Authors:  Simon Alberti; Daniel Mateju; Laura Mediani; Serena Carra
Journal:  Front Mol Neurosci       Date:  2017-03-27       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.